An immunodominant SSX-2–derived epitope recognized by CD4⁺ T cells in association with HLA-DR
J. Clin. Invest. Maha Ayyoub, et al. 113:1225 doi:10.1172/JCI20667 [Go to this article.]

Figure 4
Assessment of SSX-2_37–58–specific CD4⁺ T cells among circulating lymphocytes and tumor-infiltrated lymph nodes (TILN). (A) The presence of specific CD4⁺ T cells among peptide-stimulated PBMCs was assessed by intracellular staining with anti–IFN-γ antibodies after incubation in the absence or the presence of peptide SSX-2_37–58. (B) SSX-2_37–58–specific CD4⁺ T cells were similarly assessed in TILN, enriched by cytokine secretion–guided cell sorting, and expanded in vitro as polyclonal or monoclonal populations. Numbers in the upper right quadrants are the percentage of cytokine-producing cells among CD4⁺ T cells.